FDA Approves Inhaled Insulin (Afrezza) for Children with Diabetes
Key Questions
What is Afrezza and for which patients has the FDA approved it?
Afrezza is an inhaled insulin that provides a needle-free option for mealtime dosing. The FDA has approved it for children aged 6 and older with type 1 or type 2 diabetes.
What did the INHALE-1 trial show about Afrezza in children?
The trial demonstrated noninferior HbA1c control compared with standard therapy and higher treatment satisfaction. Pulmonary safety data were reassuring.
How could this approval affect children with diabetes?
It offers the first needle-free mealtime insulin in over a century, which may reduce injection burden and improve adherence in pediatric patients.
FDA approved Afrezza for children aged 6+ with type 1 and type 2 diabetes, the first needle-free mealtime insulin option in over a century. INHALE-1 trial showed noninferior HbA1c control and higher treatment satisfaction, with reassuring pulmonary safety. This could significantly reduce injection burden and improve adherence in pediatric populations.